CDC panel votes in favor of mpox vaccines for at-risk adults

In a unanimous vote, a CDC advisory panel voted Feb. 22 in favor of recommending mpox vaccination only for at-risk adults. 

Advertisement

“People with HIV infection or other causes of immunosuppression who have had recent or anticipate potential mpox exposure should be vaccinated against mpox,” the updated guidelines read. 

Specifically, the panel recommends “vaccination prior to exposure.” However, the CDC says that vaccination can also be given after exposure and can still offer some protection if given within four to 14 days after exposure. 

Still, “currently, CDC does not recommend routine immunization against mpox for the general public,” the organization notes. For those at risk, the CDC recommends the Jynneos vaccine, made by Bavarian Nordic, a Danish company, that prevents both smallpox and mpox.  

June is when the panel will meet next to discuss if the Jynneos vaccine should also be recommended to prevent mpox in at-risk children, CNBC reports.

Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit

Advertisement

Next Up in Public Health

Advertisement

Comments are closed.